- Home
- PRAX vs AVAH Comparison
PRAX vs AVAH Comparison
Compare PRAX & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- AVAH
- Stock Information
- Founded
- PRAX 2015
- AVAH 1984
- Country
- PRAX United States
- AVAH United States
- Employees
- PRAX N/A
- AVAH N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- AVAH Hospital/Nursing Management
- Sector
- PRAX Health Care
- AVAH Health Care
- Exchange
- PRAX Nasdaq
- AVAH Nasdaq
- Market Cap
- PRAX 950.8M
- AVAH 872.6M
- IPO Year
- PRAX 2020
- AVAH 2021
- Fundamental
- Price
- PRAX $59.22
- AVAH $3.96
- Analyst Decision
- PRAX Strong Buy
- AVAH Hold
- Analyst Count
- PRAX 10
- AVAH 6
- Target Price
- PRAX $101.00
- AVAH $5.25
- AVG Volume (30 Days)
- PRAX 399.5K
- AVAH 480.7K
- Earning Date
- PRAX 08-12-2025
- AVAH 08-07-2025
- Dividend Yield
- PRAX N/A
- AVAH N/A
- EPS Growth
- PRAX N/A
- AVAH N/A
- EPS
- PRAX N/A
- AVAH 0.03
- Revenue
- PRAX $8,122,000.00
- AVAH $2,093,077,000.00
- Revenue This Year
- PRAX N/A
- AVAH $9.80
- Revenue Next Year
- PRAX $4,434.72
- AVAH $4.77
- P/E Ratio
- PRAX N/A
- AVAH $140.25
- Revenue Growth
- PRAX 270.02
- AVAH 9.05
- 52 Week Low
- PRAX $26.70
- AVAH $2.61
- 52 Week High
- PRAX $91.83
- AVAH $6.19
- Technical
- Relative Strength Index (RSI)
- PRAX 78.36
- AVAH 33.37
- Support Level
- PRAX $53.89
- AVAH $3.95
- Resistance Level
- PRAX $59.10
- AVAH $4.11
- Average True Range (ATR)
- PRAX 3.26
- AVAH 0.15
- MACD
- PRAX 0.59
- AVAH 0.01
- Stochastic Oscillator
- PRAX 88.19
- AVAH 16.13
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About AVAH Aveanna Healthcare Holdings Inc.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.